A80-2-05 The Prognostic Utility of Mitochondrial Ribosomal Protein L47 (MRPL47) Expression in Lung Adenocarcinoma: Implications for Immune Modulation and Therapeutic Resistance to Erlotinib
Randomized trial investigates MRPL47's role in prognosis and response to erlotinib in lung adenocarcinoma, suggesting its potential as a biomarker.
Key Points
This study examines the prognostic significance of MRPL47 expression in lung adenocarcinoma and its relationship with immune modulation and resistance to erlotinib.
Accessed TCGA-LUAD cohort (n = 576) via UCSC Xena browser for clinical data and MRPL47 expression profiles.
Utilized Kaplan-Meier estimator and Cox regression analyses to evaluate overall survival.
Assessed MRPL47's impact on tumor immune microenvironment and response to erlotinib using TIMER 2.0 and CPADS.
Upregulation of MRPL47 linked to poor prognosis with hazard ratio of 1.546 (95% CI: 1.120-2.133, P = .008).
MRPL47 expression correlated with myeloid-derived suppressor cells (ρ = 0.582, P < .001).
Low MRPL47 expression associated with better response to erlotinib, evidenced by significantly lower IC50 (P = .0034).